INTRODUCTION

The COVID-19 pandemic, which to date has caused over 2,000,000 deaths worldwide, continues to grow, with hundreds of thousands of new infection cases every day. Understanding risk factors for the severe forms of the disease, and identifying people more vulnerable to the risks of infection, are crucial steps for appropriate clinical management and prevention strategies. There are an increasing number of clinical studies for COVID-19, but our current understanding in relationship to seizures and epilepsy remains limited by the relative lack of cohort studies, especially in people with pre-existing seizures and epilepsy.
3 | RESULTS

A total of 116 responses were collected, from families of children (n = 86; 74%) and adults (30; 26%) with DS, from various parts of the UK and one from Ireland. Age ranges were as follows: under 5 years (n = 23), 5–11 (n = 32), 12–17 (n = 31), 18–24 (n = 16), 25–34 (n = 11), 35–44 (n = 3). The majority (106; 91%) were shielded at the family home during lockdown, whilst a few people with DS remained at their residential home (9; 8%) and one DS person stayed at the family business (1%). 'Extremely vulnerable' status for risk of severe forms of COVID-19 was given to 50 (43%) people with DS, whilst 47 (40%) were not and no request was made, 10 (9%) were not despite a request having been made by the GP or neurologist, and 9 (8%) families were uncertain about the declared vulnerability status of their child. At least three DS people without 'extremely vulnerable' status have been shielding anyway.

Comorbidities potentially increasing the risk of COVID-19 complications were reported in some people with DS; these included a tendency to respiratory problems, for example history of recurrent chest infections, in 28 (24%); swallowing difficulties, for example percutaneous endoscopic gastrostomy (PEG) in 25 (22%); spinal abnormalities, for example scoliosis, curved or twisted spine, in 33 (29%), ranging from mild (n = 24) to severe (n = 2). Statistical analysis did not reveal significant association between any of these comorbidities and presentation of COVID-19 symptoms.

Symptoms compatible with COVID-19 were reported in 22 (19%) DS individuals, including high temperature (17; 15%), new continuous cough (9; 8%), difficulty in breathing (5; 4%), shortness of breath (4; 3%), sore throat (4; 3%), chills (3; 3%), repeated shaking with chills (3; 3%), muscle pain (3; 3%), headache (3; 3%), new loss of taste or smell (2; 2%), abdominal pain (2; 2%), and other gastrointestinal symptoms (5; 4%). In some people with DS, it was obviously difficult to assess the presence of some symptoms, such as pain or loss of taste or smell. Five people had only isolated high temperature without other symptoms, similar to their habitual episodes of chest infections in most cases. Only four individuals with symptoms had a PCR swab test, none of which was positive; none of the other symptomatic people had a swab test. Only one symptomatic person (symptoms included new continuous cough, high temperature, repeated shaking with chills, muscle pain, headache, sore throat, new loss of taste or smell) had antibody testing (but not swab testing), which was positive. One person had a number of hospitalizations during lockdown due to severe renal failure requiring dialysis; he did not have any symptoms of COVID-19 but had repeated swab tests whilst in hospital, which were positive on three occasions over about seven weeks: the infection was not considered relevant to his clinical presentation as he tested positive for the first time three weeks after he had been admitted with renal failure. The cause of renal failure was attributed to polytherapy for his epilepsy. Six other
| Children | Age range (years) | Symptoms | Medical attention required | COVID-19 testing | Change in seizure pattern |
|----------|-------------------|----------|---------------------------|-----------------|-------------------------|
| Under 5  | Difficulty breathing | Required resuscitation, ventilation, and antibody treatment in hospital | No | Increased frequency and duration |
| Under 5  | High temperature, shortness of breath | Treated with oxygen in hospital | Negative PCR swab | Increased frequency |
| Under 5  | High temperature, repeated shaking with chills, sore throat, cough | Attended emergency department, no treatment required | No | Increased frequency and duration, including longer postictal recovery |
| Under 5  | High temperature, gastrointestinal symptoms | Required ventilation in hospital | No | Increased frequency and duration |
| Under 5  | New continuous cough, high temperature | Treated with oxygen at home | Positive for antibodies | Increased frequency (responded to clobazam increase) |
| 5–11     | New continuous cough, high temperature, repeated shaking with chills, muscle pain, headache, sore throat, new loss of taste or smell | No | No | No |
| 5–11     | High temperature, generally unwell for a week | Treated with oxygen at home | No | No |
| 5–11     | New continuous cough, high temperature, difficulty breathing, muscle pain, sore throat | No | No | No |
| 5–11     | High temperature | Was already on non-invasive ventilation with BiPAP ventilator, was treated with antibiotics and oxygen at home | No | No |
| 5–11     | Headache, new loss of taste or smell | No | Negative PCR swab | No |
| 5–11     | High temperature | No | No | No |
| 5–11     | New continuous cough, high temperature | No | No | No |
| 5–11     | New continuous cough, high temperature, shortness of breath, difficulty breathing, repeated shaking with chills | Treated with oxygen and intravenous antibiotics in hospital | No | Increased frequency and duration |
| 12–17    | Gastrointestinal | No | Negative PCR swab | Unknown |
| 12–17    | High temperature and sore throat | No | No | Increased frequency |
| 12–17    | New continuous cough and flu-like symptoms | No | No | Increased frequency |
| 12–17    | New continuous cough, high temperature, shortness of breath, difficulty breathing, muscle pain, headache, abdominal pain and other gastrointestinal symptoms, ear pain, post-infectious neurological and psychological symptoms (diagnosed with PANS/ PANDAS) | Yes, oxygen saturation monitored at home; no treatment required | No | No |
| 12–17    | High temperature | No | No | Unknown |
| 12–17    | High temperature | No | No | Increased frequency |

(Continues)
asymptomatic people had negative swab tests. One asymptomatic person was admitted to hospital due to a seizure and had an antibody test which was negative.

Of the people with DS with COVID-19 symptoms, during the illness five had more frequent and longer seizures (of these, in one also a longer postictal recovery was described), six had more frequent seizures without change in seizure length, and nine had no changes in seizure frequency or length; there was no information provided for two (Table 1). Interestingly, the person asymptomatic for COVID-19 who repeatedly tested positive on swab testing was reported to have reduced seizure frequency at the time of testing.

One young person with DS, aged 12–17 years, had various symptoms including new continuous cough, high temperature, shortness of breath, difficulty breathing, muscle pain, headache and ear pain, abdominal pain and other gastrointestinal symptoms, but did not have swab or antibody testing. This individual experienced post-infectious neurological and psychological symptoms and was diagnosed with paediatric acute-onset neuropsychiatric syndrome (PANS)/paediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS). It is difficult to establish the cause with certainty.

In 9/22 (41%) people with DS and COVID-19 symptoms, medical attention was required because of their clinical symptoms of infection, either at home (n = 4) or in a hospital setting (n = 5) including intensive care (n = 2), oxygen administration and/or ventilation (n = 6), intravenous antibiotic treatment (n = 1) or just monitoring of oxygen saturation (n = 2) (Table 1).

There was no significant difference in the prevalence of symptoms between children and adults (19, 22%, in children vs 3, 10%, in adults, p = 0.115). However, we note that all the individuals who developed more severe symptoms requiring medical attention were children (four under age 5 years, four aged 5–11 years, one aged 12–17). There was no difference between the individuals who required medical attention and the ones who had milder forms, with respect to the following comorbidities: scoliosis (p = 0.310), swallowing difficulties (p = 372) and tendency to develop respiratory illnesses such as recurrent chest infections (p = 0.474).

From the open comment section (most relevant comments summarized in Table 2), additional points emerged, including parental anxiety related to shielding and risks of carers and other family members contracting the infection, anxiety related to hospital attendance, lack of support during shielding, difficulties during lockdown with changes in routine affecting mood and behaviour. On the other hand, one family reported a positive effect of the lockdown with their child being happy with the parents being the only carers and receiving support from a mental health nurse, psychologist and psychiatrist through frequent video calls, and another family reported reduced seizure frequency during lockdown possibly due to reduced infections and stress normally related to school attendance.

In one case, it was reported that the use of clobazam for increased seizure frequency was an effective treatment measure.
4 | DISCUSSION

This survey reports 22/116 (19%) individuals with DS who presented with respiratory and other symptoms during the pandemic, though the symptoms were not necessarily specific for COVID-19. The main limitation of the survey is the lack of testing which makes it difficult to establish the actual risk or presence of infection and related outcomes.

Most families have been shielding even if their child with DS was not given 'extremely vulnerable' status, and this may have contributed to prevention of infection. A few individuals with DS had been in contact with people who displayed COVID-19 symptoms, necessitating self-isolation, and the majority of them subsequently developed symptoms themselves. Symptoms were severe enough to require hospitalization in six individuals (5%), with admission to intensive care for ventilation in two. The presence of comorbidities, including susceptibility to respiratory infections, dysphagia, and spinal abnormalities, was not significantly associated with the presentation of COVID-19 symptoms. However, the statistical analysis was limited by the small sample size.

In 50% of people with DS who developed possible or probable COVID-19 symptoms, seizure worsening was reported, in terms of seizure frequency or duration or both, but no episodes of status epilepticus or other complications were described. A few families described a similar pattern of seizure exacerbation to the one that their children would have during any concurrent respiratory infection. In one person with DS, sequelae of neurological and psychiatric symptoms were reported, and a diagnosis of PANS/PANDAS was made. Again, lack of testing represents a major limitation to ascription of causality. No other post-infectious complications were reported.

Interestingly, of the five individuals who had a swab test, the only one who tested positive (on three occasions) had no COVID-19 symptoms despite severe renal failure requiring dialysis (and now awaiting kidney transplant). This is in keeping with the observation of asymptomatic individuals even among vulnerable people with epilepsy and other comorbidities. In our long-term care facility for adults with epilepsy, we recently reported two people with DS who tested positive on a PCR swab test: one required hospitalization but only had mild respiratory symptoms and has now fully recovered; the other was asymptomatic, although subjective symptoms such as loss of taste or smell could not be assessed due to cognitive impairment; neither had significant seizure deterioration.

The impact of COVID-19 in epilepsy is not fully established yet, with only a few retrospective studies reporting neurological symptoms, which do not always include seizures, in the context of severe acute respiratory syndrome due to COVID-19. Data on the impact of COVID-19 in people with pre-existing epilepsy is also limited. The impact of COVID-19 in the most severe forms of epilepsy such as DEEs and other genetic epilepsies is even less well established.

Whilst there was no difference in the age of individuals who had symptoms compatible with COVID-19, we note as an observation that all those who required medical attention were children (the majority below the age of 12 years). In a cross-sectional study of 48 critically ill children affected by COVID-19 and admitted to North American paediatric intensive care units, an uncharacterized 'neurological presentation' was reported in two children, and three had 'seizures' as pre-existing comorbidity; this study showed that rates of COVID-related severe illness and mortality in children are lower than in adults. In the paediatric population, there are a small number of children who present with a Kawasaki-like disease, also known as toxic shock syndrome, which includes persistent fever, single or multi-organ dysfunction, headache, and meningeal signs; no seizures have been reported to date associated with this Kawasaki-like disease. No such presentation was reported in our cohort. This observation should be interpreted with caution due to the small sample size and the possibly different threshold for parents to seek medical attention for younger children.

Limitations in our study include the small sample size, the retrospective design of the survey, and the lack of data on infection status and immunity due to limited testing having been performed. There is no information available on the occurrence of similar symptoms in previous years; therefore, for most subjects who developed symptoms the association with COVID-19 infection remains purely
speculative. This was not a controlled study, which would be difficult to justify. We should also note that our cohort mostly included children and young adults and this age distribution may have contributed to the benign outcome observed in all cases.

Most families in our survey or have been shielding even when not medically advised to do so, and although this may have contributed to prevention of infection, there was anecdotal evidence of social and psychological issues related to shielding (Table 1). Shielding may represent an important factor for prevention of infection, and general practitioners and epilepsy specialists could consider inclusion in the ‘extremely vulnerable group’ of people with DS who have comorbidities that may increase the risk of severe outcomes. On the other hand, if the latter are not present, there is no evidence currently that people with DS are at increased risk of severe outcomes from COVID-19, and shielding in these circumstances seems unjustified and may carry adverse psychosocial consequences. Tolerance of shielding may vary significantly across people with DS, and we do not know its longer term consequences on mood and behaviour. The impact on caregivers has also not been clearly established yet. Given the clinical spectrum of severity in DS, a holistic risk/benefit assessment of shielding should be conducted on an individual basis, including health and social care needs. The physical and mental wellbeing of families and carers should also be considered in such an assessment.

Testing at least of symptomatic people, and regular surveillance for people living in residential care homes, is a crucial factor to reduce the spread of infection, and thus limiting the impact of the pandemic in vulnerable people.6

Although from our study we cannot establish what preventative factors may have been present, we observed an infection rate, determined by compatible symptoms, of 19%, with no deaths and benign outcome in most cases despite the underlying complex condition. We could cautiously conclude that DS may not put affected individuals at increased risk of severe outcomes, compared with those with other health conditions,23 assuming that shielding and other infection prevention and controls are put in place.

Should there be a further wave of infection, we recommend prompt testing of symptomatic individuals, and regular surveillance for people living in residential care facilities. Declaration of ‘extremely vulnerable status’ and shielding should be considered on an individual basis, following assessment of comorbidities that may increase the risk of severe outcomes. We do not know what adverse effects there may be of prolonged or repeated shielding, and such consequences need consideration. There is no treatment for COVID-19 yet. A number of studies are investigating potential therapeutic targets. Vaccination seems the most promising strategy, with 33 candidate vaccines under clinical evaluation.24 Although vaccination is often a precipitating factor of seizure onset in DS,25 there is now established evidence that vaccination-associated earlier seizure onset does not alter disease course in DS.26,27 Subsequent vaccinations do not significantly affect clinical and cognitive outcome.28 whilst the risk of subsequent vaccination-associated seizures seems to be vaccine-specific.27 In conclusion, our study provides additional evidence that risk of severe outcomes of COVID-19 in people with DS may not be not significantly increased, although medical attention may still be required. However, prospective studies are lacking.

ETHICS STATEMENT

We abided by national regulations in the UK where the survey was undertaken. Data handling information was provided at the start of the survey and detailed in the following link: https://www.dravet.org.uk/privacy-policy/. This meets the information and consent requirements for survey data sharing, as stated in the UK Data Service regulation (https://www.ukdataservice.ac.uk/manage-data/legal-etrical-consent-data-sharing/surveys.aspx). No personal information is included in this report of the results of the survey.

ACKNOWLEDGEMENTS

We thank all the families who participated to the survey. S Balestrini was supported by the Muir Maxwell Trust and Epilepsy Society.

CONFLICT OF INTEREST

None of the authors have competing interests to disclose.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Simona Balestrini https://orcid.org/0000-0001-5639-1969

REFERENCES

1. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy (Dravet Syndrome). In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence, 4th edn. London: John Libbey Eurotext Publishers; 2005:89-113.
2. Kim Y, Bravo E, Thirnbeck CK, et al. Severe peri-ictal respiratory dysfunction is common in Dravet syndrome. J Clin Invest. 2018;128:1141-1153.
3. Shmuely S, Sisodiya SM, Gunning WB, Sander JW, Thijs RD. Mortality in Dravet syndrome: A review. Epilepsy Behav. 2016;64:69-74.
4. Huang S, Wu C, Jia Y, et al. COVID-19 outbreak: The impact of stress on seizures in patients with epilepsy. Epilepsia. 2020;61(9):1884-1893.
5. Public Health England, Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-people-from-covid-19-guidance-on-shielding-and-protecting-extremely-vulnerable-people-from-covid-19-definition; last accessed 2020, August 31.
6. Balestrini S, Koepf MJ, Gandhi S, et al. Clinical outcomes of SARS-CoV-2 pandemic in long-term care facilities for people with epilepsy: observational study. Epilepsy Behav. 2020;107602.
7. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683-690.
8. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019
(COVID-19) infection admitted to us and Canadian pediatric intensive care units. *JAMA Pediatr.* 2020;174:1-6.

9. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet.* 2020;395:1607-1608.

Verdini L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet.* 2020;395:1771-1778.

11. Lu L, Xiong W, Liu D, et al. New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study. *Epilepsia.* 2020;61:49-53.

12. Abdulsalam MA, Abdulsalam AJ, Shehab D. Generalized Status Epilepticus as a Possible Manifestation of COVID-19. *Acta Neurol Scand.* 2020;142(4):297-298.

13. Anand P, Al-Faraj A, Sader E, et al. Seizure as the presenting symptom of COVID-19: A retrospective case series. *Epilepsy Behav.* 2020;112:107335.

14. Dugue R, Cay-Martinez KC, Thakur KT, et al. Neurologic manifestations in an infant with COVID-19. *Neurology.* 2020;94:1100-1102.

15. Elgamy S, Kamel MG, Ghozy S, Khalil A, Morra ME, Islam SMS. First case of focal epilepsy associated with SARS-coronavirus-2. *J Med Virol.* 2020;92(10):2238-2242.

16. Hepburn M, Mullaguri N, George P, et al. Acute symptomatic seizures in critically ill patients with COVID-19: is there an association? *Neurocrit Care.* 2020;9:1-5.

17. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis.* 2020;94:55-58.

18. Vollono C, Rollo E, Romozzi M, et al. Focal status epilepticus as unique clinical feature of COVID-19: a case report. *Seizure.* 2020;78:109-112.

19. Cabezudo-Garcia P, Ciano-Petersen NL, Mena-Vázquez N, Pons-Pons G, Castro-Sánchez MV, Serrano-Castro PJ. Incidence and case fatality rate of COVID-19 in patients with active epilepsy. *Neurology.* 2020;95:e1417-1425.

20. Assenza G, Lanzone J, Brigo F, et al. Epilepsy Care in the Time of COVID-19 Pandemic in Italy: Risk Factors for Seizure Worsening. *Front Neurol.* 2020;11:737.

21. Alhhotani A, Siddiqui MI, Almntashri F, Baothman R. The effect of COVID-19 pandemic on seizure control and self-reported stress on patient with epilepsy. *Epilepsy Behav.* 2020;112:107323.

22. Aledo-Serrano Á, Mingorance A, Jiménez-Huete A, et al. Genetic epilepsies and COVID-19 pandemic: Lessons from the caregiver perspective. *Epilepsia.* 2020;61:1312-1314.

23. Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *Lancet Glob Health.* 2020;8:e1003-1017.

24. World Health Organization. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines; last accessed August 31, 2020.

25. Tro-Baumann B, von Spiczak S, Lotte J, et al. A retrospective study of the relation between vaccination and occurrence of seizures in Dravet syndrome. *Epilepsia.* 2011;52:175-178.

26. McIntosh AM, McMahon J, Dibbens LM, et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. *Lancet Neurol.* 2010;9:592-598.

27. Verbeek NE, van der Maas NA, Sonsma AC, et al. Effect of vaccination on seizure risk and disease course in Dravet syndrome. *Neurology.* 2015;85:596-603.

28. Zamponi N, Passamonti C, Petrelli C, et al. Vaccination and occurrence of seizures in SCN1A mutation-positive patients: a multicenter Italian study. *Pediatr Neurol.* 2014;50:228-232.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Balestrini S, Wilson G, Eldred C, Evans H, Sisodiya SM. The impact of COVID-19 in Dravet syndrome: A UK survey. *Acta Neurol Scand.* 2021;143:389-395. [https://doi.org/10.1111/ane.13405](https://doi.org/10.1111/ane.13405)